Share-based Payment Arrangement, Expense of Beam Therapeutics Inc. from 31 Mar 2019 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Beam Therapeutics Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2019 to 31 Dec 2025.
  • Beam Therapeutics Inc. Share-based Payment Arrangement, Expense for the quarter ending 31 Dec 2025 was $20,448,000, a 32% decline year-over-year.
  • Beam Therapeutics Inc. Share-based Payment Arrangement, Expense for the twelve months ending 31 Dec 2025 was $94,244,000, a 22% decline year-over-year.
  • Beam Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2025 was $94,244,000, a 22% decline from 2024.
  • Beam Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2024 was $120,662,000, a 22% increase from 2023.
  • Beam Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2023 was $98,647,000, a 17% increase from 2022.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Beam Therapeutics Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $94,244,000 $20,448,000 -$9,770,000 -32% 01 Oct 2025 31 Dec 2025 10-K 24 Feb 2026 2025 FY
Q3 2025 $104,014,000 $22,747,000 -$6,812,000 -23% 01 Jul 2025 30 Sep 2025 10-Q 04 Nov 2025 2025 Q3
Q2 2025 $110,826,000 $24,367,000 -$7,237,000 -23% 01 Apr 2025 30 Jun 2025 10-Q 05 Aug 2025 2025 Q2
Q1 2025 $118,063,000 $26,682,000 -$2,599,000 -8.9% 01 Jan 2025 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q4 2024 $120,662,000 $30,218,000 +$7,601,000 +34% 01 Oct 2024 31 Dec 2024 10-K 24 Feb 2026 2025 FY
Q3 2024 $113,061,000 $29,559,000 +$3,724,000 +14% 01 Jul 2024 30 Sep 2024 10-Q 04 Nov 2025 2025 Q3
Q2 2024 $109,337,000 $31,604,000 +$5,326,000 +20% 01 Apr 2024 30 Jun 2024 10-Q 05 Aug 2025 2025 Q2
Q1 2024 $104,011,000 $29,281,000 +$5,364,000 +22% 01 Jan 2024 31 Mar 2024 10-Q 06 May 2025 2025 Q1
Q4 2023 $98,647,000 $22,617,000 +$118,000 +0.52% 01 Oct 2023 31 Dec 2023 10-K 24 Feb 2026 2025 FY
Q3 2023 $98,529,000 $25,835,000 +$3,626,000 +16% 01 Jul 2023 30 Sep 2023 10-Q 05 Nov 2024 2024 Q3
Q2 2023 $94,903,000 $26,278,000 +$4,700,000 +22% 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024 2024 Q2
Q1 2023 $90,203,000 $23,917,000 +$5,882,000 +33% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q4 2022 $84,321,000 $22,499,000 +$6,997,000 +45% 01 Oct 2022 31 Dec 2022 10-K 25 Feb 2025 2024 FY
Q3 2022 $77,324,000 $22,209,000 +$9,241,000 +71% 01 Jul 2022 30 Sep 2022 10-Q 08 Nov 2023 2023 Q3
Q2 2022 $68,083,000 $21,578,000 +$11,126,000 +106% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 $56,957,000 $18,035,000 +$13,387,000 +288% 01 Jan 2022 31 Mar 2022 10-Q 10 May 2023 2023 Q1
Q4 2021 $43,570,000 $15,502,000 +$8,695,000 +128% 01 Oct 2021 31 Dec 2021 10-K 27 Feb 2024 2023 FY
Q3 2021 $34,875,000 $12,968,000 +$9,956,000 +331% 01 Jul 2021 30 Sep 2021 10-Q 07 Nov 2022 2022 Q3
Q2 2021 $24,919,000 $10,452,000 +$7,683,000 +277% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 $17,236,000 $4,648,000 +$1,856,000 +66% 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022 2022 Q1
Q4 2020 $15,380,000 $6,807,000 +$4,750,000 +231% 01 Oct 2020 31 Dec 2020 10-K 28 Feb 2023 2022 FY
Q3 2020 $10,630,000 $3,012,000 +$983,000 +48% 01 Jul 2020 30 Sep 2020 10-Q 08 Nov 2021 2021 Q3
Q2 2020 $9,647,000 $2,769,000 +$696,000 +34% 01 Apr 2020 30 Jun 2020 10-Q 10 Aug 2021 2021 Q2
Q1 2020 $8,951,000 $2,792,000 +$1,923,000 +221% 01 Jan 2020 31 Mar 2020 10-Q 11 May 2021 2021 Q1
Q4 2019 $7,028,000 $2,057,000 01 Oct 2019 31 Dec 2019 10-K 28 Feb 2022 2021 FY
Q3 2019 $2,029,000 01 Jul 2019 30 Sep 2019 10-Q 10 Nov 2020 2020 Q3
Q2 2019 $2,073,000 01 Apr 2019 30 Jun 2019 10-Q 12 Aug 2020 2020 Q2
Q1 2019 $869,000 01 Jan 2019 31 Mar 2019 10-Q 12 May 2020 2020 Q1

Beam Therapeutics Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $94,244,000 -$26,418,000 -22% 01 Jan 2025 31 Dec 2025 10-K 24 Feb 2026 2025 FY
2024 $120,662,000 +$22,015,000 +22% 01 Jan 2024 31 Dec 2024 10-K 24 Feb 2026 2025 FY
2023 $98,647,000 +$14,326,000 +17% 01 Jan 2023 31 Dec 2023 10-K 24 Feb 2026 2025 FY
2022 $84,321,000 +$40,751,000 +94% 01 Jan 2022 31 Dec 2022 10-K 25 Feb 2025 2024 FY
2021 $43,570,000 +$28,190,000 +183% 01 Jan 2021 31 Dec 2021 10-K 27 Feb 2024 2023 FY
2020 $15,380,000 +$8,352,000 +119% 01 Jan 2020 31 Dec 2020 10-K 28 Feb 2023 2022 FY
2019 $7,028,000 01 Jan 2019 31 Dec 2019 10-K 28 Feb 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.